52 Week Lows – 14th April 2025
Stocks hitting 52 week lows and 52 week highs are closely watched by investors looking for value and high growth respectively. Bargain hunters look for profitable companies hitting 52 week lows, whereas stocks hitting 52 week highs provide fertile ground for growth seeking investors. Here are the stocks hitting 52 week lows and 52 week…
CSL Shares (ASX: CSL) Hit 52 Week Low, Looking For Support
CSL’s shares (ASX: CSL) have started the year with the bears leading the way, with a 0.26% decline today bringing the cumulative YTD loss to 8.86%. With a new 52 week low of $253.04 being hit on the day, this continues the trend seen towards the second half of 2024, where the share price fell…
CSL Rated a Buy Post FY24 Results
Leading blood plasma and vaccine manufacturer CSL (ASX:CSL) has been tagged as a ‘buy’ by major brokerage firms following its financial outcomes for the fiscal year 2024 (FY24). The company, renowned for its growth trajectory, recently disclosed its revenue and earnings, alongside providing forward-looking guidance that stands to shape investor expectations. CSL reported a robust…
CSL Shares (ASX:CSL) Hit New 52-Week High On Strong Day For ASX 200
Shares of CSL Ltd (ASX: CSL), one of Australia’s leading biotechnology companies, have soared to a new 52-week high, marking a significant milestone. Today, the ASX 200 Index also achieved a record pinnacle, hitting an all-time high of 8,037.3 points, with shares across the board, including those of CSL Ltd, climbing by 0.73%. CSL Ltd,…
CSL Limited (ASX: CSL)
Company Information CSL Limited (ASX: CSL) CSL Limited is an Australian biotechnology company specializing in rare and serious diseases, influenza vaccines, and treatments for iron deficiency and nephrology. It comprises three main segments: CSL Behring, which focuses on plasma products, gene therapies, and recombinants; CSL Seqirus, dedicated to influenza vaccines and pandemic services;…
Can CSL Maintain its Growth Momentum?
CSL is considered one of the premier growth stocks on the ASX. Half Year 2024 Financial Results showed an both revenue and profit increases, beating market expectations. The share price sold off on unrelated negative news. In December of 2021 CSL added global kidney care biotech Vifor to its existing revenue generating segments – blood…
CSL Limited (ASX: CSL) Trading Near Three-Year Lows
The COVID-19 Pandemic negatively impacted CSL’s blood plasma business. The company now faces high-interest rates, inflationary pressures, and foreign currency headwinds noted in a February market update. The ASX stock price went into a tailspin from which it has not recovered. CSL Limited, a global giant biotechnology company, has added a third revenue-generating business to…
Should you buy CSL (ASX: CSL) on the Dips?
CSL is one of the largest stocks on the ASX by market cap. The company’s status as a premiere pharmaceutical, biotechnology, and life sciences company gives CSL strong tailwinds. The company has not missed a dividend payment in a decade. Given the ageing populations around the world, CSL’s two operating divisions – CSL Behring providing…
